论文部分内容阅读
目的探讨胸腺肽α_1用于治疗重症肺炎的效果。方法将56例重症肺炎患者按随机数字表法分为治疗组和对照组,各28例。两组患者入院后均给予常规治疗,治疗组在上述基础上皮下注射1.6 mg胸腺肽α_1,1次/d,持续7 d,分别检测治疗前、治疗第7天患者免疫细胞水平、C反应蛋白((;RP】、血清降钙素原(PCT)、血白细胞计数(WBC)水平的变化。结果两组患者CRP、PCT、WBC和CD8~+较治疗前明显下降(P<0.05),CD4~+、CD4~+/CD8~+比值较治疗前有明显升高;治疗组各指标与对照组比较,差异有统计学意义(P<0.05);治疗组机械通气时间和入住ICU时间明显较对照组短(P<0.05)。结论在常规治疗的基础上使用胸腺肽α_1能提高重症肺炎患者的细胞免疫功能,改善炎症指标,缩短机械通气时间、入住ICU时间。
Objective To investigate the effect of thymosin α_1 in the treatment of severe pneumonia. Methods Fifty-six patients with severe pneumonia were divided into treatment group and control group according to random number table method, 28 cases in each. The patients in both groups were given routine treatment after admission. The treatment group was given subcutaneous injection of 1.6 mg thymosin α_1, once daily for 7 days on the above basis, and the level of immune cells, the level of C-reactive protein (P <0.05), and the levels of CD4 ~ + T lymphocytes (CRP), PCT, WBC and CD8 + in the two groups were significantly lower than those before treatment (P <0.05). The time of mechanical ventilation and ICU stay in the treatment group were significantly longer than those in the control group (P <0.05) .Conclusion Thymosin α 1 can improve the cellular immune function, improve the inflammation index, shorten the time of mechanical ventilation and stay in ICU on the basis of routine treatment.